SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15094)2/15/1998 2:18:00 AM
From: Torben Noerup Nielsen  Read Replies (1) | Respond to of 32384
 
Henry,

>at this time the paper does not have a definitive reason on why
>Targretin did so well. Several clinical trials were proposed as well
>as several molecular mechanisms.

While the underlying reason is not all that important in terms of getting the drug to market, it is of great importance for Ligand. If they can unravel the molecular mechanism, they will have gained the high ground since this would open the whole problem up to rational drug design.

Why do I have this feeling that a lot of Ligand's scientists are working feverishly on just that question....

Cheers, Torben



To: Henry Niman who wrote (15094)2/15/1998 11:48:00 PM
From: Vector1  Respond to of 32384
 
Henry,
The info on the Rat model used is very helpful.
Although I try and be a dispassionate investor it is hard not to fall in love with LGND's potential. Success with either the Diabetes indication or Breast Cancer will propel LGND into the ranks of those few biotechs with multiple billion dollar valuations. Success in both is a winning lottery ticket.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News